Interleukin‐29 uses a type 1 interferon‐like program to promote antiviral responses in human hepatocytes

Sean E. Doyle, Heidi Schreckhise, Kien Khuu‐Duong, Katherine Henderson, Robert Rosler, Harold Storey, Lena Yao, Hong Liu, Fariba Barahmand‐pour, Pallavur Sivakumar, Chung Chan, Carl Birks, Don Foster, Christopher H. Clegg, Perdita Wietzke‐Braun, Sabine Mihm, Kevin M. Klucher – 27 September 2006 – Interleukin‐28A (IL‐28A), IL‐28B and IL‐29 are a family of class II cytokines that stimulate antiviral responses through a heterodimeric receptor that is distinct from the type I interferon (IFN) receptor.

Uracil‐tegafur as an adjuvant for hepatocellular carcinoma: A randomized trial

Kiyoshi Hasegawa, Tadatoshi Takayama, Masayoshi Ijichi, Yutaka Matsuyama, Hiroshi Imamura, Keiji Sano, Yasuhiko Sugawara, Norihiro Kokudo, Masatoshi Makuuchi – 27 September 2006 – Frequent recurrence of hepatocellular carcinoma (HCC) after surgery remains a major clinical problem. This randomized controlled trial evaluated whether postoperative adjuvant therapy with oral uracil‐tegafur (UFT) prevents recurrence of HCC.

Contribution of hepatic adenosine A1 receptors to renal dysfunction associated with acute liver injury in rats

Zhi Ming, Yi‐Jun Fan, Xi Yang, W. Wayne Lautt – 27 September 2006 – Acute liver injury is associated with renal insufficiency, whose mechanism may be related to activation of the hepatorenal reflex. We previously showed that intrahepatic adenosine is involved in activation of the hepatorenal reflex to restrict urine production in both healthy rats and in rats with cirrhosis. The aim of the present study was to test the hypothesis that activation of intrahepatic adenosine receptors is involved in the pathogenesis of the renal insufficiency seen in acute liver injury.

Optimizing staging for hepatocellular carcinoma before liver transplantation: A retrospective analysis of the UNOS/OPTN database

Richard B. Freeman, Abigail Mithoefer, Robin Ruthazer, Khanh Nguyen, Anthony Schore, Ann Harper, Erick Edwards – 26 September 2006 – Assignment of liver allocation priority for hepatocellular carcinoma is predicated on accurate imaging staging. We analyzed radiographically defined stage (radiologic stage [RS]) at listing and most recent extension and pathologic stage (PS) data from 789 liver transplant recipients for whom no pretransplant ablative treatment was given. There were no predetermined imaging or pathological protocols in this retrospective analysis of wait list data.

12‐month follow‐up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus

Gary Levy, Gian Luca Grazi, Fernando Sanjuan, Youmin Wu, Ferdinand Mühlbacher, Didier Samuel, Styrbjorn Friman, Robert Jones, Guido Cantisani, Federico Villamil, Umberto Cillo, Pierre Alain Clavien, Goran Klintmalm, Gerd Otto, Stephen Pollard, P Aiden McCormick, LIS2T Study Group – 26 September 2006 – The LIS2T study was an open‐label, multicenter study in which recipients of a primary liver transplant were randomized to cyclosporine microemulsion (CsA‐ME) (Neoral) (n = 250) (monitoring of blood concentration at 2 hours postdose) C2 or tacrolimus (n = 245) (monitoring of trough drug blood l

Transjugular intrahepatic portosystemic shunt for treatment of intractable colonic ischemia associated with portal hypertension: A bridge to liver transplantation

Jonathan A. Schneider, Edward A. White, Derek C. Welch, LeAnn S. Stokes, David S. Raiford – 26 September 2006 – A 64‐year‐old man with portal hypertension secondary to hepatic nodular transformation was awaiting liver transplantation when he presented with severe, unrelenting abdominal pain, fever, and hypotension. Computed tomographyrevealed pneumatosis within the cecum and ascending colon. Because of his advanced liver disease and the perceived high likelihood of a poor outcome after colonic resection, he was managed medically.

Subscribe to